Move to topTop
September 26, 2017

ALISO VIEJO, CA (September 26, 2017) - MicroVention, a wholly owned subsidiary of Terumo Corporation and a global neurovascular company, today announced that the Grand Opening of its New Innovation Center was held on Monday, September 25. The opening of the new facility, located in the heart of the Summit Office Campus, also signifies the Company's official return to Aliso Viejo: MicroVention was founded there in 1997, originally occupying buildings very close to the new location and is also commemorating their 20-year anniversary as a Company.

The celebration welcomed Terumo Corporation's Takayoshi Mimura, Chairman; Hikaru Samejima, President, Cardiac & Vascular Group; and Jim Takeuchi, President & CEO of Terumo Americas. Representatives of many neighboring businesses, members of the Aliso Viejo City Council, and contributing vendors also attended the festivities. In 2006, Terumo acquired MicroVention into their family of Companies to leverage unique, proprietary technologies and facilitate additional focus on new technologies.

"The opening of our new Worldwide Innovation Center is an important milestone for MicroVention and Terumo," said Rich Cappetta, MicroVention President & Chief Executive Officer. "The New Innovation Center will promote increased physician collaboration and technology development, both of which lead to our ultimate goal of improving patient care."

MicroVention's new 205,000 square-foot, 5.13-acre complex was built to support the growth and expansion of products offered under the MicroVention brand for the foreseeable future. The new complex, which can accommodate more than 800 associates, consolidates the majority of the MicroVention operations and functions, with manufacturing continuing at the Tustin, CA facility. Among its many features are expansive clean room facilities, research and development laboratories and a state-of-the-art neuroradiology imaging lab. The complex also includes an 822-stall, five-story parking structure. MicroVention is a Global Company with worldwide direct sales and distribution outlets in over 75 countries.

"The new building solidifies the strong belief Terumo has in MicroVention's positive future," said Mr. Mimura. "Terumo is enthusiastic about its commitment to continued innovation, looks forward to supporting MicroVention's growth, and is thrilled to celebrate MicroVention's return to Aliso Viejo."

The grand opening ceremony and ribbon-cutting was highlighted by speeches from Mr. Cappetta, Mr. Mimura and Mr. Takeuchi, as well as Matt Fitz, Senior Vice President of R&D and Operations; Rob Greene, Founder & Chief Technology Officer; Russ Parker, Managing Director of Parker Properties; and Bill Phillips, Aliso Viejo City Councilman.

As part of its anniversary ceremonies, MicroVention also exhibited a Time Capsule with 20 years of the Company's history to be opened in 2038 as a way of celebrating what the next 20 years may bring to the industry and Company.

About MicroVention, Inc.

Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve treatment of cerebrovascular diseases. In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention into their family of Companies. Terumo's acquisition of MicroVention allowed both Companies to leverage their unique, proprietary technologies toward an increased focus on treating cerebrovascular diseases.

Headquartered in California, MicroVention products are today sold in more than 75 nations through a direct sales organization alongside strategic distribution partnerships. Manufacturing facilities are located in Aliso Viejo and Tustin, California; San José, Costa Rica; and Saint-Germain-en-Laye, France.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.